Table 2 Univariate and multivariate Cox regression analysis of risk factors for thymoma survival

Sex

Female

Reference

Male

1.329

0.568–3.111

0.512

Age

1.013

0.982–1.045

0.418

Myasthenia gravis

1.024

0.429–2.445

0.958

CCI

0

Reference

Reference

1&2&3

2.793

1.206–6.468

0.016

2.169

0.827–5.697

0.116

WHO pathological classification

A + AB + MNT

Reference

B + MIX + C

2.249

0.665–7.602

0.192

Masaoka-Koga staging

I + II

Reference

Reference

III + IV

8.472

3.307–21.704

0.000

2.011

0.420–9.637

0.382

Surgical approach

OT

Reference

VATS

0.492

0.209–1.160

0.105

Resection status

R0

Reference

Reference

None R0

6.818

2.511–18.518

0.000

0.736

0.188–2.880

0.660

Perioperative complications

3.070

1.224–7.700

0.017

1.597

0.563–4.531

0.379

Postoperative therapy

2.766

0.930–8.222

0.067

1.160

0.277–4.855

0.839

Recurrence

16.011

6.297–40.711

0.000

7.826

1.842–33.250

0.005

Sex

Female

Reference

Male

1.329

0.568–3.111

0.512

Age

1.013

0.982–1.045

0.418

Myasthenia gravis

1.024

0.429–2.445

0.958

CCI

0

Reference

Reference

1&2&3

2.793

1.206–6.468

0.016

2.129

0.805–5.634

0.128

WHO pathological classification

A + AB + MNT

Reference

B + MIX + C

2.249

0.665–7.602

0.192

TNM staging

I + II

Reference

Reference

III + IV

7.622

3.106–18.704

0.000

1.513

0.337–6.792

0.589

Surgical approach

OT

Reference

VATS

0.492

0.209–1.160

0.105

Resection status

R0

Reference

Reference

None R0

6.818

2.511–18.518

0.000

0.723

0.183–2.851

0.643

Perioperative complications

3.070

1.224–7.700

0.017

1.590

0.551–4.592

0.391

Postoperative therapy

2.766

0.930–8.222

0.067

1.262

0.310–5.136

0.745

Recurrence

16.011

6.297–40.711

0.000

9.433

2.235–39.818

0.002